American International Group Inc. Lowers Holdings in Kenvue Inc. (NYSE:KVUE)

American International Group Inc. lowered its position in shares of Kenvue Inc. (NYSE:KVUE) by 3.5% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 437,772 shares of the company’s stock after selling 16,096 shares during the quarter. American International Group Inc.’s holdings in Kenvue were worth $9,425,000 as of its most recent filing with the SEC.

Other institutional investors have also modified their holdings of the company. Beaumont Financial Advisors LLC boosted its holdings in Kenvue by 3.0% in the 4th quarter. Beaumont Financial Advisors LLC now owns 17,532 shares of the company’s stock worth $377,000 after acquiring an additional 509 shares during the period. Pinnacle Bancorp Inc. increased its position in Kenvue by 51.3% in the fourth quarter. Pinnacle Bancorp Inc. now owns 1,552 shares of the company’s stock worth $33,000 after buying an additional 526 shares during the period. Tradition Wealth Management LLC increased its position in Kenvue by 2.8% in the fourth quarter. Tradition Wealth Management LLC now owns 21,278 shares of the company’s stock worth $458,000 after buying an additional 575 shares during the period. Dfpg Investments LLC increased its position in Kenvue by 2.3% in the fourth quarter. Dfpg Investments LLC now owns 26,659 shares of the company’s stock worth $567,000 after buying an additional 589 shares during the period. Finally, Mutual Advisors LLC increased its position in Kenvue by 6.1% in the fourth quarter. Mutual Advisors LLC now owns 10,606 shares of the company’s stock worth $228,000 after buying an additional 612 shares during the period. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Kenvue Price Performance

Shares of NYSE:KVUE opened at $18.52 on Wednesday. The firm has a market capitalization of $35.45 billion and a PE ratio of 23.74. The company has a current ratio of 0.99, a quick ratio of 0.68 and a debt-to-equity ratio of 0.66. Kenvue Inc. has a 1-year low of $17.75 and a 1-year high of $26.74. The business’s 50 day moving average is $19.33 and its 200-day moving average is $20.08.

Kenvue (NYSE:KVUE) last posted its quarterly earnings results on Tuesday, May 7th. The company reported $0.28 earnings per share for the quarter, topping analysts’ consensus estimates of $0.25 by $0.03. Kenvue had a net margin of 9.63% and a return on equity of 21.06%. The firm had revenue of $2.89 billion for the quarter, compared to the consensus estimate of $3.79 billion. The business’s quarterly revenue was down 24.9% compared to the same quarter last year. Sell-side analysts predict that Kenvue Inc. will post 1.18 earnings per share for the current year.

Kenvue Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, May 22nd. Stockholders of record on Wednesday, May 8th were paid a $0.20 dividend. The ex-dividend date was Tuesday, May 7th. This represents a $0.80 annualized dividend and a dividend yield of 4.32%. Kenvue’s dividend payout ratio is currently 102.56%.

Analysts Set New Price Targets

KVUE has been the subject of several recent analyst reports. Sanford C. Bernstein initiated coverage on Kenvue in a research note on Thursday, April 11th. They issued an “underperform” rating and a $18.00 price target for the company. Citigroup reissued a “neutral” rating and set a $21.00 price objective on shares of Kenvue in a report on Tuesday, May 28th. William Blair assumed coverage on Kenvue in a report on Wednesday, April 3rd. They set a “market perform” rating on the stock. The Goldman Sachs Group assumed coverage on Kenvue in a report on Friday, March 1st. They set a “neutral” rating and a $20.00 price objective on the stock. Finally, HSBC increased their price objective on Kenvue from $20.00 to $21.00 and gave the company a “hold” rating in a report on Wednesday, May 8th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $23.09.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.